All articles tagged with #hiv prevention
A woman with multiple bisexual boyfriends is concerned about STI risks from unprotected oral sex with men who also have anonymous partners. Experts advise regular testing, including throat and rectal swabs, and consider interventions like doxy PEP and PrEP to reduce risks of bacterial STIs and HIV. The article emphasizes that all sexual activity carries some risk, but proper testing and prevention strategies can help manage it.
South Africa, Eswatini, and Zambia have begun using a groundbreaking HIV prevention injection, lenacapavir, which reduces transmission risk by over 99.9% and is administered twice a year, marking a significant advancement in HIV prevention efforts in Africa, though access and cost remain challenges.
Advocates warn that proposed budget cuts to HIV programs in the US could reverse decades of progress in combating HIV/AIDS, emphasizing the importance of continued funding and policy support to prevent a rise in new infections and protect those living with HIV.
The article discusses how recent cuts in international aid from the US, UK, and Europe have severely impacted HIV/AIDS care in sub-Saharan Africa, leading to increased infections and deaths, especially among key populations like LGBTQ+ individuals and young women. Despite some signs of recovery and increased domestic funding, the overall situation remains dire, emphasizing the need for political courage and sustainable local responses to combat the epidemic effectively.
The UK government has announced a £170 million plan to end new HIV transmissions by 2030, including opt-out testing in emergency departments, home testing kits via NHS app, and targeted re-engagement of those out of care, aiming to reduce stigma and improve early diagnosis.
Gilead Sciences' new HIV prevention shot, Yeztugo, shows high efficacy but faces challenges in adoption due to its high $28,000 price tag, with CVS Caremark declining to include it in its formulary despite other insurers moving forward, raising concerns about affordability and disease eradication efforts in the U.S.
Campaigners in Northern Ireland are advocating for the introduction of cabotegravir injections, a long-acting HIV prevention drug, to help meet the goal of ending new HIV cases by 2030, with the drug already being adopted in England, Wales, and Scotland as an alternative to daily PrEP pills.
A new long-acting HIV prevention injection, cabotegravir, is set to be approved in England and Wales, offering an alternative to daily pills for those at risk who cannot take oral Prep, with rollout expected soon to help reach the goal of ending HIV transmissions by 2030.
South Africa's health minister announced the introduction of lenacapavir, the world's first twice-yearly HIV prevention injection, with an initial limited supply of nearly half a million doses starting in April 2026, amid concerns over funding cuts and licensing issues affecting local manufacturing and access.
A new drug called lenacapavir, approved for HIV prevention, offers a twice-yearly injection with near-vaccine efficacy, potentially transforming HIV prevention efforts worldwide, especially in low-income countries, but its impact will depend heavily on political and logistical factors.
Jamaica is considering a pilot program for the FDA-approved injectable HIV drug lenacapavir, which could significantly improve adherence and prevention efforts, especially among young people, with plans for free access in the public health system and potential scaling up based on pilot outcomes.
A new twice-yearly HIV prevention injection, lenacapavir, is set to be more affordable and accessible in resource-limited countries like Nigeria, sparking mixed reactions due to skepticism and conspiracy theories, despite potential benefits in reducing HIV transmission and improving adherence.
Cheap supplies of the groundbreaking HIV prevention injection lenacapavir will be available in many poorer countries from 2027 at $40 per patient per year, potentially transforming efforts to end the global HIV epidemic, with support from major health organizations and generic drug manufacturers.
The Gates Foundation has partnered with an Indian manufacturer to reduce costs and expand access to a groundbreaking HIV prevention tool, aiming to benefit millions and improve global health outcomes.
The CDC strongly recommends the use of injectable lenacapavir, administered every 6 months, as an effective and safe option for HIV preexposure prophylaxis in persons weighing at least 35 kg, based on high-certainty evidence from clinical trials showing near 100% efficacy in preventing HIV infection.